Kovaltry under the microscope: how does it perform in everyday care?
NCT ID NCT02941783
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study looked at how safe and effective Kovaltry is for people with hemophilia A when used in routine medical practice. Researchers tracked 230 patients for side effects and bleeding episodes. The goal was to gather real-world information, not to test a new treatment.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- Kovaltry (a recombinant clotting factor VIII)
- What this could lead to
- If results confirm real-world safety and effectiveness, it may support continued use of Kovaltry for managing hemophilia A.
- What could go wrong
- This is an observational, post-marketing study with no control group. It cannot prove that Kovaltry works better than other treatments, and results may not apply to all patients.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HEMOPHILIA A are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Many Locations
Multiple Locations, Japan
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- A Once-a-Week shot could transform hemophilia Care—Even for those with inhibitors
- Can a new clotting factor offer better bleed protection for severe hemophilia?
- Do newer hemophilia drugs protect joints better? study aims to find out
- Newborn screening study aims to catch rare diseases at birth
- Could home blood tests transform hemophilia care? study seeks patient views
- New clotting factor shows promise for hemophilia a bleeds